维普期刊资源整合服务平台（V6.5）

84篇 您的检索式：作者名="Meropol N"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	SALTZ L B MEROPOL N J LOEHRER P J Sr	2004	J Clin Oncol2004，22，7：	1
2	Phase lI trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz LB Meropol N J Loehrer PJ Sr	2004	J Clin Oncol2004，22，7：	1
3	Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer显示文摘	AGGARWAL C MEROPOL N J PUNT C J		0，，：	1
4	Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel显示文摘	Rothenberg ML Meropol N J Poplin EA	2001	J Clin Oncol2001，19，18：	1
5	Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 显示文摘	GIANTONIO B J CATALANO P J MEROPOL N J	2007	J Clin Oncol2007，25，12：	1
6	Phase II trial of cetuximab in patients with refraetory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz L B Meropol N J Loehrer P J	2004	J Clin Oncol2004，22，7：	1
7	Phase II trial of Cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	SALTZ L B MEROPOL N J LOEHRER Sr P J	2004	J Clin Oncol2004，22，7：	1
8	Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz L Meropol N Loehrer P	2004	J Clin Oncol2004，22，7：	1
9	Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer 显示文摘	MEROPOL N J GOLD P J DIASIO R B	2006	J Clin Oncol2006，24，25：	1
10	Preliminary studies of a novel oralfluoropyrimidine carbamate: capecitabine显示文摘	BUDMAN D R MEROPOL N J REIGNER B	1998	CUnOncol1998，16，5：	1
11	Thymidine phos- phorylase expression is associated with response to eapecitabineplus irinotecan in patients with metastatic colorectal cancer显示文摘	MEROPOL N J GOLD P J DIASIO R B	2006	J Clin Oncol2006，24，25：	1
12	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor 显示文摘	Saltz LB Meropol N J Loehrer PJ Sr	2004	J Clin On col2004，22，11：	1
13	Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer 显示文摘	Goldberg R M Meropol N J Tabernero J	2009	Gastrointest Cancer Res2009，3，52：	1
14	Changing patterns of bone and brain metastases in patients with colorectal cancer显示文摘	Sundermeyer ML Meropol N J Rogatko A	2005	Clin Colorectal Cancer2005，5，2：	1
15	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor 显示文摘	Saltz LB Meropol N J Loehrer PJ Sr	2004	J Clin Oncol2004，22，7：	1
16	Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200显示文摘	Giantonio B J Catalano P J Meropol N J	2007	J ClinOncol2007，25，12：	1
17	PhaseⅠpharmacokinetic and biologic correlative study of mapatumumab,a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor显示文摘	Tolcher A W Mita M Meropol N J		0，，11：	1
18	Expression of epiregulin and amphiregulin and K-ras mutation sta- tus predict disease control in metastatic colorectal cancer patients treated with cetuximab 显示文摘	KHAMBATA-FORD S GARRETT C R MEROPOL N J	2007	J Clin Oncol2007，25，22：	1
19	High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group(ECOG) study E3200 (abstract2) 显示文摘	Giantonio B J Catalano PJ Meropol N J	2005	J Clin Oncol2005，23，16：	1
20	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab 显示文摘	Khambata-Ford S Garrett CR Meropol N J	2007	J Chn Oncol2007，25，22：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示